Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Cancer Immunol Res. 2014 May 6;2(8):789–799. doi: 10.1158/2326-6066.CIR-13-0162

Figure 1. MiR-17/20a inhibits tumor growth in vivo.

Figure 1

(A) Growth curves of control (miR-Ctrl) and miR-17~92 cluster (miR-17~92) tumors by subcutaneous injection of CT26/miR-Ctrl and CT26/miR-17~92 monoclonal cells into BALB/c mice (upper panel) or NOD-scid IL2Rg-/- mice (lower panel 5 mice per group). Error bars represent standard deviation (±SD) (two-way ANOVA; ** p<0.01). (B) Growth curves of control (miR-Ctrl) and miR-17~92 cluster (miR-17~92) tumors by orthotopical injection of 4T1/miR-Ctrl and 4T1/miR-17~92 monoclonal cells into the mammary fat pads in BALB/c mice (upper panel) or NOD-scid IL2Rg-/- mice (lower panel 5 mice per group). Error bars represent standard deviation (±SD) (two-way ANOVA; ** p<0.01).